Accuray and RaySearch Agree to Collaboration Integrating RayStation Software with Accuray Platforms to Accelerate Accuray's Online Adaptive Capabilities

Accuray and RaySearch entered a definitive agreement to jointly commercialize online adaptive radiation therapy, with Accuray purchasing RayStation software licenses totaling $8 million. The initial integration targets Accuray's Radixact platform, with a future extension to CyberKnife, combining imaging, treatment delivery, planning and workflow software to support personalized cancer treatment. The partnership could strengthen Accuray's adaptive-therapy offering and expand adoption across its installed base, although commercialization and regulatory-clearance risks remain.

Analysis

The near-term earnings effect for ARAY is likely immaterial: the committed software spend is an input cost, while any revenue upside depends on conversion of installed-base sites into upgrades, recurring software/service attach, and ultimately system pull-through. The more important mechanism is reduced workflow friction—historically the gating factor in adaptive radiotherapy—potentially improving ARAY's win rate versus Elekta (EKTA-B.ST) and Siemens Healthineers/Varian (SHL.DE) where hospitals prioritize a single-vendor, validated workflow over hardware specifications. Margin benefit, if it comes, is a 6-18 month story and requires software pricing to exceed the incremental license, integration, and field-support burden.

RAY.B has the cleaner initial economics because the arrangement validates its software as an OEM-like layer and supplies a defined order value, but investors should not annualize that purchase. The strategic upside is distribution into ARAY's account base; the strategic risk is customer concentration and a long validation cycle that delays broader license revenue. For ARAY, this also creates vendor dependency: RaySearch can capture part of the economics from any adaptive-treatment adoption rather than ARAY owning the full software stack.

Consensus may overvalue the "adaptive" label before evidence of clinical throughput and reimbursement. Clinics will adopt only if re-planning time, staffing requirements, and treatment-slot utilization improve enough to offset implementation disruption; superior targeting alone does not ensure capital-budget approval. The key 1-3 month catalyst is management disclosure of launch timing, pilot sites, pricing/attach model, and regulatory milestones; absence of those specifics should limit a sustained rerating.

Key Decisions for Investors

• Keep ARAY on watch rather than chase a press-release move. Consider a tactical long only after management quantifies installed-base conversion targets or discloses paid pilot orders; reassess if the next earnings call shows no software/service backlog contribution or launch timing slips.
• Prefer RAY.B over ARAY for a 6-18 month thematic position if liquidity permits: it has more direct software monetization leverage and potential channel expansion. Size modestly because the disclosed order is non-recurring; exit or reduce if subsequent reporting does not show additional ARAY-linked bookings or deferred revenue.
• For a relative-value expression, consider long RAY.B / short EKTA-B.ST over 3-6 months only after checking valuation, borrow, and currency exposure. The thesis is that a successful third-party workflow layer weakens the value of closed-platform differentiation; falsification is Elekta demonstrating comparable adaptive workflow adoption or ARAY/RaySearch failing to provide commercial milestones.
• Set an event alert for regulatory clearance and named-site deployment. A delay beyond announced commercialization expectations, or evidence that adaptive sessions reduce clinic throughput, is the clearest signal to avoid both longs despite favorable strategic messaging.